Press Releases

Application Could Provide U.S. and International Patent Coverage for PL9643, Palatin’s Lead Compound for Dry Eye Disease Phase 2/3 Clinical Trial Currently Planned for Mid-2021 Feb 10, 2021, 07:30 ET CRANBURY, N.J., Feb. 10, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the […]

Statistically Significant Improvement in Moderate-to-Severe Patients for Multiple Sign and Symptom Measures Phase 2/3 Clinical Trial Currently Planned for Mid-2021 Conference Call and Webcast Today at 8:00 a.m. ET Dec 15, 2020, 07:00 ET CRANBURY, N.J., Dec. 15, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based

– Regained North American Rights to Vyleesi® for HSDD with Palatin Receiving $12 Million from AMAG Plus $4.3 Million Due March 31, 2021 – Phase 2 Clinical Results of PL9643 for the Treatment of Dry Eye Disease on Track for December 2020 – $86.6 Million in Cash and Cash Equivalents as of September 30, 2020

Nov 12, 2020, 07:30 ET CRANBURY, N.J., Nov. 12, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2021 operating results on Tuesday, November 17, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive

– $82.9 Million in Cash and Cash Equivalents at June 30, 2020 – Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi® in July 2020 Resulted in Palatin Receiving $12 Million from AMAG Plus $4.3 Million Due March 31, 2021 – Phase 2 Study Data of PL9643 for the Treatment of Dry Eye Disease

Sep 24, 2020, 16:00 ET CRANBURY, N.J., Sept. 24, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2020 operating results on Monday, September 28, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by

Sep 10, 2020, 17:47 ET CRANBURY, N.J., Sept. 10, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced today that it will be presenting at the H.C. Wainwright & Co., 22nd Annual

Aug 13, 2020, 16:12 ET CRANBURY, N.J., Aug. 13, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced that it participated in Canaccord Genuity’s 40th Annual Growth Conference in a Fireside Chat today

Data Anticipated Q4 2020 Aug 05, 2020, 07:30 ET CRANBURY, N.J., Aug. 5, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced completion of enrollment of its Phase 2 study with

Palatin Regains All Rights Company to Receive $16.3 Million from AMAG Teleconference and Webcast to be held on July 27, 2020 Jul 27, 2020, 07:00 ET CRANBURY, N.J., July 27, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin